Liver function studies in children with acute lymphocytic leukemia after cessation of therapy.
We investigated liver function in 27 children with acute lymphocytic leukemia (ALL) after cessation of therapy. Induction therapy consisted of prednisolone+vincristine (VP regimen) alone (16 patients) or with addition of daunorubicin (4 patients) or L-asparaginase (7 patients). Patients treated with VP regimen received short courses of VP regimen every 12 weeks for the first year of maintenance. Twenty-five patients remained in first complete remission and had completed 3-year maintenance therapy with methotrexate (MTX) and 6-mercaptopurine (6-MP) 1-7 years prior to this study. Twenty-three patients had received transfusions of packed red blood cells or fresh whole blood (1-11 units; median: 2 units) but none had evidence of either hepatitis B or hepatitis C. Alanine aminotransferase (ALT), which was measured every 3 months during maintenance therapy, had values more than three times the upper limit of the normal range in 25% of the measurements in more than half of the patients. However, by 3 months after the completion of maintenance therapy, ALT had normalized in all patients and remained normal in all but two patients until the time of this study. Serum bilirubin, serum albumin, and prothrombin time were all within normal limits. Fasting and 2-hour postprandial total serum bile acids were high in 5 of 13 patients and in 6 of 13 patients, respectively. The ratio of cholic acids+deoxycholic acids to chenodeoxycholic acids+lithocholic acids was below 1 in all but two patients, whereas this ratio was above 1 in all controls. Our bile acid profile results indicate the necessity of careful long-term follow-up of survivors of ALL treated with hepatotoxic chemotherapy during childhood.
Bessho
F
F
Department of Pediatrics, University of Tokyo Hospital, Japan.
Kinumaki
H
H
Yokota
S
S
Hayashi
Y
Y
Kobayashi
M
M
Kamoshita
S
S
D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001215:Asparaginase / Q000008:administration & dosage; D001647:Bile Acids and Salts / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury / Q000503:physiopathology*; D002648:Child; D003630:Daunorubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000503:physiopathology*; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D009423:Nervous System Neoplasms / Q000188:drug therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000503:physiopathology*; D011239:Prednisolone / Q000008:administration & dosage; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
D001647:Bile Acids and Salts; D014750:Vincristine; D011239:Prednisolone; D015122:Mercaptopurine; D000410:Alanine Transaminase; D001215:Asparaginase; D008727:Methotrexate; D003630:Daunorubicin